Saiba
Saiba Biotech is a pioneering company focused on developing innovative vaccine technologies, including vaccines for peanut allergy and COVID-19. They utilize proprietary platform technologies such as virus-like particles (VLP) to create effective immunotherapies. The company's mission is to advance health through cutting-edge biotech solutions, aiming to bring new vaccines to market for various immune conditions.
Industries
Nr. of Employees
small (1-50)
Products
COVID-19 VLP-based vaccine candidate
A vaccine candidate based on an immunologically optimized virus-like particle platform that demonstrated preclinical induction of neutralizing antibodies in animal models.
Peanut allergy VLP-based vaccine candidate
A VLP-based vaccine candidate developed for peanut allergy that progressed to partnered clinical development and whose clinical advancement was referenced in partner IND filings.
COVID-19 VLP-based vaccine candidate
A vaccine candidate based on an immunologically optimized virus-like particle platform that demonstrated preclinical induction of neutralizing antibodies in animal models.
Peanut allergy VLP-based vaccine candidate
A VLP-based vaccine candidate developed for peanut allergy that progressed to partnered clinical development and whose clinical advancement was referenced in partner IND filings.
Services
Technology licensing and partnerships
Out-licensing platform technology and establishing collaborative agreements with external developers to broaden application of the platform.
Collaborative vaccine R&D and preclinical studies
Design and execution of preclinical vaccine studies in animal models, including immunogenicity and biomarker assessments.
CDMO coordination for process development and production
Coordination with contract development and manufacturing partners for development and production of vaccine candidates.
Preclinical biomarker and ex vivo assay services
Execution and analysis of ex vivo biomarker studies to assess immunological responses to vaccine candidates.
Technology licensing and partnerships
Out-licensing platform technology and establishing collaborative agreements with external developers to broaden application of the platform.
Collaborative vaccine R&D and preclinical studies
Design and execution of preclinical vaccine studies in animal models, including immunogenicity and biomarker assessments.
CDMO coordination for process development and production
Coordination with contract development and manufacturing partners for development and production of vaccine candidates.
Preclinical biomarker and ex vivo assay services
Execution and analysis of ex vivo biomarker studies to assess immunological responses to vaccine candidates.
Expertise Areas
- VLP-based vaccine platform development
- Preclinical immunology and vaccine R&D
- Vaccine process development and CDMO coordination
- Technology licensing and partnership management
Key Technologies
- Virus-like particle (VLP) vaccine platform
- Animal immunogenicity and neutralization assays
- Ex vivo biomarker assays
- CDMO-enabled process development and scale-up